- The company's shareholders have suffered a series of dilutive events and the upcoming vote for doubling the authorized shares creates nightmares for them.
- However, adoption of the company's technology is accelerating, which, in combination with the existing pipeline, could create liquidity problems in the future.
- I believe H2 2021 will be a turning point for T2 Biosystems, as we will see some nice developments regarding their Lyme and Resistance panels.
- A potential vote pass on the authorization of additional shares will lift any concerns about the company's liquidity, which, in combination with the existing pipeline, will result in significant share price appreciation.
For further details see:
T2 Biosystems: This Shareholder Vote Could Dispel Bankruptcy Concerns